| Gevo believes that the Argonne National Laboratory GREET model is the best available standard of scientific-based measurement for life cycle inventory or LCI | Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements |
|---|---|
| Of note, Japan is the first country to approve sofpironium bromide, which also represents the first topical prescription product to be marketed for the treatment of primary axillary hyperhidrosis in the country | Non-GAAP information is not prepared under a comprehensive set of accounting rules and therefore, should only be read in conjunction with financial information reported under U |
About Hyperhidrosis Hyperhidrosis is a debilitating, life-altering medical condition where a person sweats beyond what is physiologically required for thermoregulation of the body.
15| MDT to report its financial results for the first quarter ended March 31, 2021 and provide an update on recent corporate highlights | is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis |
|---|---|
| The RNG plant is expected to be online in 2022 and begin to generate cash then | NASDAQ: GEVO today announced financial results for the first quarter of 2021 and recent corporate highlights |
Investors must be able to afford the loss of their entire investment.
14| These liquid hydrocarbons can be used for drop-in transportation fuels such as gasoline, jet fuel and diesel fuel, that when burned have potential to yield net-zero greenhouse gas emissions when measured across the full life cycle of the products | 3 million in prepaids to third-party clinical research organizations as part of conducting its U |
|---|---|
| multi , HoF, Graduate Research Professor Emeritus, University of Florida | is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases |
Brickell Investor Contact:Dan FerryLifeSci Advisors 617 430-7576daniel lifesciadvisors.